Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2262867 | 1.00 | BTK (0.53) | BTKGAACTSKKMT2AL3MBTL1 | |
| SCHEMBL2262870 | 1.00 | BTK (0.53) | BTKGAACTSKKMT2AL3MBTL1 | |
| SCHEMBL19364082 | 1.00 | BTK (0.53) | BTKGAACTSKKMT2AL3MBTL1 | |
| SCHEMBL470721 | 1.00 | BTK (0.53) | BTKGAACTSKKMT2AL3MBTL1 | |
| SCHEMBL471721 | 0.90 | BTK (0.55) | BTKGAACTSKKMT2AL3MBTL1 | |
| SCHEMBL14805424 | 0.90 | BTK (0.55) | BTKGAACTSKKMT2AL3MBTL1 | |
| SCHEMBL509424 | 0.90 | BTK (0.55) | BTKGAACTSKKMT2AL3MBTL1 | |
| SCHEMBL7876216 | 0.84 | BTK (0.51) | BTKGAACTSKKMT2AL3MBTL1 | |
| SCHEMBL18766144 | 0.82 | BTK (0.54) | BTKGAACTSKKMT2AL3MBTL1 | |
| SCHEMBL17398093 | 0.81 | BTK (0.56) | BTKGAACTSKKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220089571-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2022-03-24 | — | — | US | disclosed |
| US-9278920-B2 | Pleuromutilin derivatives for use in the treatment of diseases mediated by microbes | NABRIVA THERAPEUTICS AG (AT) | 2016-03-08 | — | — | US | disclosed |
| US-20130274329-A1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG (AT) | 2013-10-17 | — | — | US | disclosed |
| EP-2433926-A1 | Pleuromutilin derivatives for use in the treatment of diseases mediated by microbes | Nabriva Therapeutics AG (AT) | 2012-03-28 | — | — | EP | disclosed |
| WO-2012031307-A1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG (AT) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274329-A1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | Q6ZSR9, CUTA, MC4R | BTK 4138/4885GAA 1343/4885CTSK 3786/4885 |
| US-20220089571-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | BTK 2427/4885GAA 2767/4885CTSK 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.